Compare TYRA & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CNMD |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 1987 |
| Metric | TYRA | CNMD |
|---|---|---|
| Price | $25.49 | $41.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | $32.17 | ★ $53.67 |
| AVG Volume (30 Days) | 511.4K | ★ 600.9K |
| Earning Date | 11-05-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 1.95% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $1,347,470,000.00 |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | N/A | $0.64 |
| P/E Ratio | ★ N/A | $20.07 |
| Revenue Growth | N/A | ★ 4.61 |
| 52 Week Low | $6.42 | $38.32 |
| 52 Week High | $26.34 | $74.70 |
| Indicator | TYRA | CNMD |
|---|---|---|
| Relative Strength Index (RSI) | 71.18 | 49.23 |
| Support Level | $24.88 | $39.00 |
| Resistance Level | $26.34 | $40.78 |
| Average True Range (ATR) | 1.27 | 1.18 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 81.62 | 88.18 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.